On 28 August 2006, orphan designation (EU/3/06/394) was granted by the European Commission to Analytica International GmbH, Germany, for autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin for the treatment of follicular lymphoma.
The sponsorship was transferred to Analytica International Inc. - Outcomes Research and Pricing, Germany, in May 2011 and subsequently to Biovest Europe Limited, United Kingdom, in September 2011.
EU/3/06/394: Public summary of positive opinion for orphan designation of autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin for the treatment of follicular lymphoma (PDF/124.28 KB)
First published: 02/04/2009
Last updated: 14/06/2012
EMEA/COMP/280125/2006 Rev. 3
Autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin
|Disease / condition||
Treatment of follicular lymphoma
|Date of decision||
|Orphan decision number||
Sponsor's contact details
70 Great Bridgewater St.
Manchester M1 5ES
Telephone: +44 845 497 8663
Telefax: +44 845 497 8888
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.